Evidence map›Paper›PMID 39548213›Full record

ArticleScientific reports2024

Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody.

Hang Ke, Tao Yang, Faming Zhang, Cen Chen, Jingjing Wang, Jinping Liu, Xiaoyu An, Lingxin Xiong, Xianfei He, Lei Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hang KeHanx Pharmaceuticals, Inc, Hangzhou, China.
Tao YangHanx Pharmaceuticals, Inc, Hangzhou, China.
Faming ZhangHanx Pharmaceuticals, Inc, Hangzhou, China.
Cen ChenHanx Pharmaceuticals, Inc, Hangzhou, China.
Jingjing WangCrown Bioscience, Inc, Taicang, China.
Jinping LiuCrown Bioscience, Inc, Taicang, China.
Xiaoyu AnCrown Bioscience, Inc, Taicang, China.
Lingxin XiongCrown Bioscience, Inc, Taicang, China.
Xianfei HeShanghai Model Organisms Center (SMOC), Shanghai, China.
Lei ZhangHanx Pharmaceuticals, Inc, Hangzhou, China.
Qi-Xiang LiHanx Pharmaceuticals, Inc, Hangzhou, China. henry.li@hanxbio.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Certain immune-checkpoint inhibitors have a narrow therapeutic window (TW) as cancer therapeutics, and engineered dual-/multi-targeting agents could potentially widen the TW to bring true clinical benefits. We report a new rationally-designed bispecific-antibody (BsAb), HX009, simultaneously targeting PD1 and CD47 to improve both the efficacy and safety over the respective single-targeting agents by grafting the extracellular domain of SIRPα onto the parental anti-PD1-monoclonal antibody, HX008. This resulted in an IgG4-based "2 × 2" symmetric structure but with an intentionally-reduced CD47-binding affinity, suggesting a novel candidate cancer immunotherapy. Specifically, HX009 has binding affinity constant of 8.951 × 10

Indexed as

Antibodies, BispecificCD47 AntigenProgrammed Cell Death 1 ReceptorAnimalsAntibodies, MonoclonalAntigens, DifferentiationFemaleHumansImmunotherapyMacaca fascicularisMiceReceptors, ImmunologicXenograft Model Antitumor AssaysAntibodies, BispecificAntibodies, MonoclonalAntigens, DifferentiationCD47 AntigenCD47 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, ImmunologicSIRPA protein, humanAMLAnti-tumor activityBsAbCynomolgus monkeyImmunotherapyInnate/adaptive ICIsPharmacokineticsToxicologyXenograft and humanized syngeneic tumor models

Identifiers

PMID39548213
PMCPMC11567960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.